VHT vs VXX
Vanguard Health Care ETF vs iPath Series B S&P 500 VIX Short-Term Futures ETN
VHT$347.68
Vanguard Health Care ETF
US health care sector stocks.
Expense: 0.09%Yield: 1.35%
VXX$17.91
iPath Series B S&P 500 VIX Short-Term Futures ETN
VIX short-term futures, hedge / speculation.
Expense: 0.89%Yield: 0.00%
Quick take
- • VHT has the lower expense ratio at 0.09% vs 0.89% for VXX.
- • VHT pays a higher dividend yield (1.35%).
Side-by-side metrics
| Metric | VHT | VXX |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.09% | 0.89% |
Dividend yield Trailing 12-month yield. | 1.35% | 0.00% |
AUM Assets under management — bigger funds are typically more liquid. | $23.73B | $566M |
YTD return | 22.17% | -28.15% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.46 | -58.66 |
P/E ratio | 32.41 | — |
Last price | $347.68 | $17.91 |
Inception | — | — |
Issuer | Vanguard | Barclays |
VHT top holdings
Top holdings · VHT
| LLY | Eli Lilly and Co | 12.93% |
| JNJ | Johnson & Johnson | 8.78% |
| ABBV | AbbVie Inc | 6.45% |
| MRK | Merck & Co Inc | 5.01% |
| UNH | UnitedHealth Group Inc | 4.65% |
| TMO | Thermo Fisher Scientific Inc | 3.50% |
| AMGN | Amgen Inc | 3.18% |
| GILD | Gilead Sciences Inc | 2.58% |
| ABT | Abbott Laboratories | 2.40% |
| PFE | Pfizer Inc | 2.27% |
Sector breakdown · VHT
Technology0.0%
Financial Services0.0%
Industrials0.0%
Healthcare100.0%
VXX top holdings
Holdings data unavailable for VXX.
About VHT
VHT (Vanguard Health Care ETF) is US health care sector stocks. Managed by Vanguard, the fund carries $23.7B in assets under management, an expense ratio of 0.09%, a dividend yield of 1.35%. Its largest holding is Eli Lilly and Co (LLY), which represents 12.9% of the portfolio. Technology is the fund's largest sector exposure at 0.0%.
About VXX
VXX (iPath Series B S&P 500 VIX Short-Term Futures ETN) is VIX short-term futures, hedge / speculation. Managed by Barclays, the fund carries $566M in assets under management, an expense ratio of 0.89%.